Published in final edited form as:

Hum Immunol. 2019 January ; 80(1): 37–43. doi:10.1016/j.humimm.2018.04.013.

B cell MHC class II signaling: A story of life and death

Divya Sai Katikaneni^a and Lei Jina^{a,*}

^aDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Florida, Gainesville, FL 32610, United States

Abstract

MHC class II regulates B cell activation, proliferation, and differentiation during cognate B cell-T cell interaction. This is, in part, due to the MHC class II signaling in B cells. Activation of MHC Class II in human B cells or “primed” murine B cells leads to tyrosine phosphorylation, calcium mobilization, AKT, ERK, JNK activation. In addition, crosslinking MHC class II with monoclonal Abs kill malignant human B cells. Several humanized anti-HLA-DR/MHC class II monoclonal Abs entered clinical trials for lymphoma/leukemia and MHC class II-expressing melanomas. Mechanistically, MHC class II is associated with a wealth of transmembrane proteins including the B cell-specific signaling proteins CD79a/b, CD19 and a group of four-transmembrane proteins including tetraspanins and the apoptotic protein MPYS/STING. Furthermore, MHC class II signals are compartmentalized in the tetraspanin-enriched microdomains. In this review, we discuss our current understanding of MHC class II signaling in B cells focusing on its physiological significance and the therapeutic potential.

Keywords

B cells; MHC class II; CD79a/b; MPYS

1. Introduction

B cells include B-1 and B-2 cells. B-1 cells spontaneously secrete natural IgM and reside mainly in pleural and peritoneal cavities. B-2 cells (herein referred to as B cells), on the other hand, mediate the majority of T cell-dependent antibody response. Besides secreting antibodies, B cells express MHC class II and serve as antigen-presenting cells (APCs) for CD4⁺ T cells. The APCs function of B cells has been demonstrated recently using B cells-specific MHC class II conditional knockout mice (CD19^{cre}-MHC II^{fl/fl}) [1–3]. These studies found that MHC class II on B cells contributes to the development, differentiation, and effector functions of CD4⁺ T cells in response to T cell-dependent antigen [3], during the development of autoimmune disease such as MRL.Fas^{lpr} lupus model [1] and the multiple sclerosis model experimental autoimmune encephalomyelitis [2].

*Corresponding author. Lei.jin@medicine.ufl.edu (L. Jin).

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be considered as a potential conflict of interest.

During cognate B cell -T cell interaction, MHC Class II is also critical for B cell activation, proliferation, and differentiation [1]. In comparison to MHC II⁻ B cells, MHC II⁺ B cells had a substantial advantage in proliferation, differentiation into plasmablasts, or germinal center B cells, and isotype switching [1]. B cell-activating signals during cognate B-T cell interaction is mainly mediated by CD40. However, T-cell dependent IgM production can proceed in the absence of CD40 signals [4–7]. Several lines of evidence suggested that MHC class II, besides their antigen presentation ability, are signaling molecules that may promote T-cell dependent IgM production during the cognate B-T cell interaction [8–12].

MHC class II delivers a variety of signals to B cells [13]. The cytoplasmic tails of MHC class II are required for the induction of 3',5'-cyclic adenosine monophosphate (cAMP) [14] and ubiquitination [15]. In this review, we focus on two distinct MHC class II signal pathways that are independent of the cytoplasmic tails or the antigen recognition domains (ARD) of MHC class II. i) the activation, proliferation (life) signals mediated by MHC class II-associated CD79a/b during cognate B-T cells interaction (Fig. 1). ii) The anti-tumor activity (death) of anti-MHC class II/HLA-DR monoclonal antibodies (mAbs) (Fig. 2). During the cognate B cell-T cell interaction, signaling via MHC class II in B cells lead to Src-family kinase activation, Ca²⁺ mobilization, and B cell proliferation [13] (Fig. 1). These responses are mainly mediated by MHC class II-associated CD79a/b in B cells, which depends on the connecting peptide region of the MHC class II [9,16]. Anti-MHC class II mAbs kill malignant B cells, which is independent of the cytoplasmic tails of MHC class II [16–20] (Fig. 2). Consequently, human HLA-DR is a therapeutic target for lymphoma/leukemia and MHC class II-expressing melanomas [18,21–27]. The four-transmembrane protein MPYS, also known as STING (stimulator of the interferon genes), seemed to play an important role in mediating MHC class II mAbs induced murine B lymphoma cell death [28].

2. Discussion

2.1. In vivo “priming” induces CD79a/b-MHC class II association in spleen B cells and contributes to the early Ag-specific IgM response

Lang P. et al. first found that MHC class II molecules can associate with CD79a/b heterodimers, which was previously found only in the B cell receptor (BCR) complex [9]. Notably, BCR and MHC class II are associated with different pools of CD79a/b [9]. Signal through MHC class II only activates MHC class II-associated CD79a/b, not CD79a/b in the BCR complex [9]. Importantly, the MHC class II/CD79a/b association requires prior treatment of IL-4 or antigen engagement via BCR, referred to here as “priming” [9]. The authors further suggest that MHC class II-associated CD79a/b were from recycling BCR [9]. This notion could be significant. Very small amounts of MHC class II on cell surface bind to antigen-specific-peptide capable of stimulating antigen-specific CD4⁺ T cells. It is tempting to suggest that the CD79a/b is transferred from IgM to MHC class II while the antigen is passed on from IgM to MHC class II. Thus, the CD79a/b associated MHC class II may define these small numbers of antigen-specific MHC class II complex that stimulates TCR.

Jordan M.B. et al. later found that vaccine adjuvant aluminum hydroxide (alum) induced MHC class II/CD79a/b complex in B cells in vivo [8]. They further identified a spleen IL-4-

producing Gr1⁺ CD11B⁺ myeloid population that is responsible for the inducible MHC class II/CD79a/b association in alum-treated B cells [8]. Depleting this Gr-1⁺ cells or deleting the IL-4 gene caused decreased thymus-dependent, early antigen-specific IgM Ab responses while the antigen-specific IgG1 response was not affected [8].

Wang H. et al. later identified the spleen Gr-1⁺ IL-4⁺ cells as eosinophils [29]. They found that alum failed to prime B cell to elicit MHC class II signaling in the dbIGATA BALB/c mice [29]. The dbIGATA BALB/c mice lack mature eosinophils as a result of a mutation in the promoter region of the *gata-1* gene. Adoptive transfer of WT eosinophils to the dbIGATA BALB/c mice fully restored the alum-elicited MHC class II signaling in splenic B cells and the early antigen-specific IgM response in vivo [29].

McKee A. et al., around the same time, found that similar to alum, schistosome eggs also induced the generation of IL-4⁺ Gr-1⁺ innate cells in spleen and primed B cells for MHC class II/CD79a/b signaling [30]. Interestingly, unlike alum, schistosome eggs did not induce CD4⁺ T cells priming to a co-administered antigen, which suggested that the MHC class II/CD79a/b signaling was not sufficient for promoting T helper cells activation [30]. Furthermore, they demonstrated that the IL-4⁺Gr-1⁺ innate cells were predominantly responsible for the suppression of Th1 response, i.e. the production of IgG2a/2c while the Th2 response in terms of IgG1 remained intact after the depletion of the Gr-1⁺ IL-4⁺ innate cells [30]. Notably, Alum, schistosome egg and IL-4 promote mainly Th2 response. It is unknown if MHC class II/CD79a/b association occurs during a Th1 response. Do IFN γ , IL-12p70, like IL-4, promote MHC class II/CD79a/b association in ex vivo B cells? If so, which cell population is responsible for the priming of B cells during the Th1 response in vivo? If not, can B cell MHC class II transmit signaling during a Th1 response in vivo?

HLA-DR, not HLA-DP or HLA-DQ, engagements induce calcium mobilization and tyrosine phosphorylation in human B cell lines and primary human B cells [10,31,32]. Different from murine splenic B cells, human B cells do not require “priming” for HLA-DR-induced calcium mobilization [10,31,32]. Vaccinations are common in the modern society. Alum is included in many human vaccines. Thus, human B cells are likely already “primed” due to the repeated vaccinations. Consistently, a significant portion of human PBMC B cells is antigen-experienced IgM⁺ or IgG⁺ memory B cells [33]. The molecular mechanism by which HLA-DR-induces calcium mobilization and tyrosine phosphorylation is not clear. Whether human CD79a/b mediate HLA-DR signaling, as they do in murine B cells, remains to be determined.

In summary, alum induces IL-4-producing eosinophils in the spleen that primes murine B cells to elicit MHC class II- CD79a/b association and signaling. The MHC class II/CD79a/b signaling then may play an important role in optimizing thymus-dependent, early antigen-specific IgM Ab responses.

2.2. MHC class II/CD79a/b signaling in primed B cells

CD79a/b is a heterodimer with disulfide bonds, which in association with IgM form BCR. BCR has two main functions. First is antigen recognition. The IgM-bound antigen is internalized, processed, loaded onto MHC class II and expressed on the cell surface as MHC

class II-peptide complex to stimulate antigen-specific CD4⁺ T cells [34]. The second function of BCR is signal transduction, which is mediated by CD79a/b [34]. The MHC class II/CD79a/b signaling largely mimics the BCR signaling.

MHC class II/CD79a/b complex is activated by TCR on the T cell surface [9]. Though B cells are capable of recognizing and responding to soluble antigen, the predominant form of antigen that mediates B cell activation in vivo is on the membrane surface of APCs, such as dendritic cells (DCs), follicular DCs, and macrophages [35–38]. Thus, both MHC class II and IgM use CD79a/b to transduce signals from membrane-bound molecules.

CD79a/b are a transmembrane protein with cytoplasmic tails bearing an immunoreceptor tyrosine-based activation motif (ITAM) of consensus YxxL/Ix(6–8)YxxL/I [39]. The ITAM is also found in CD3, ζ -chains of the T cell receptor (TCR) and is a common mechanism used by many molecules to transduce activating signals. Upon MHC class II aggregation, the dual tyrosine residues in CD79a (ENLY₁₈₂EGLNLDD-CSMY₁₉₃EDI) and CD79b (DHTYEGLDIDQTATYEDI) are phosphorylated by Src family protein tyrosine kinases spleen tyrosine kinase (Syk), Fyn and Lyn [39]. The dual-phosphorylated ITAMs of CD79a/b serve as docking sites for the tandem SH2 domains containing signaling molecules including Syk, phospholipase-C γ 2 (PLC γ 2), Bruton's tyrosine kinase, phosphoinositide 3-kinase (PI-3 K) [39]. The CD79a/b signaling can lead to many distinct outcomes, including survival, differentiation, proliferation or apoptosis [39].

2.3. Positive and negative regulator of the MHC class II/CD79a/b signaling in B cells

Similar to the BCR signaling, the MHC class II signaling is tightly regulated (Fig. 1). MHC class II is associated with BCR co-receptors CD19, CD22, and CD45 that modulates BCR signaling [40,41]. Using the K46 mouse B lymphoma cells, which exhibit a primed MHC class II signaling phenotype, Greer S., et al., showed that CD45 was critical for MHC class II signaling [41]. MHC class II-mediated Src family kinase Lyn activation was abrogated, and the Ca²⁺ mobilization was drastically reduced in the absence of CD45 expression [41].

CD19 and CD22 are positive and negative regulators of BCR signaling respectively. Bobbitt E.R. et al. showed that aggregation of MHC class II in activated B cells rapidly induced tyrosine phosphorylation on CD19 and CD22 [40]. Phosphorylated CD19 recruited Vav and PI-3 K, that enhanced MHC class II signaling [40]. In contrast, phosphorylated CD22 recruited SHP-1 and inhibited MHC class II signaling [40]. Co-ligation of CD19 with MHC class II in primed splenic B cells resulted in a significant increase in calcium mobilization while co-ligation of CD22 with MHC class II decreased calcium mobilization [40]. Thus, similar to BCR signaling, MHC class II signaling in B cells is modulated by CD19 and CD22.

SCIMP (SLP65/SLP76, Csk-interacting membrane protein) is a transmembrane adaptor protein regulating MHC class II induced sustained ERK activation [42]. SCIMP does not appear to directly bind MHC class II [42]. Instead, it binds tetraspanin CD37, CD53 and CD81 and likely associates with MHC class II via the tetraspanin-enriched microdomains [42]. SCIMP is tyrosine phosphorylated by Src family kinases and recruits the adaptor protein SLP65 and Grb2 [42]. However, SCIMP deficiency did not affect MHC class II-

induced calcium mobilization [42]. Unlike CD19, CD22 or CD45, only MHC class II, not BCR, activation led to SCIMP tyrosine phosphorylation [42]. Interestingly, Luo L. et al., recently found that SCIMP directly binds TLR4 in macrophage and is required for TLR4-induced IL-6 and IL-12p40 but not TNF production [43].

MPYS/STING is a four-transmembrane protein that associates with MHC class II in B cells [28]. MPYS has an antiproliferative and proapoptotic function, which will be discussed in Section 4. Meanwhile, MPYS contains an immunoreceptor tyrosine-based inhibition motif (ITIM) (SIY₂₄₅ELL) and negatively regulates MHC class II signaling in B cells [28]. The ITIM consensus sequence is S/I/V/LxYxxI/V/L [44]. Tyrosine phosphorylation on ITIM by Src kinase results in the recruitment of phosphotyrosine phosphatases, such as SHP-1 and SHP-2, or the SH2-domain-containing inositol phosphatase, SHIP, which inhibits tyrosine phosphorylation and calcium flux [44]. Indeed, anti-MHC class II mAbs induce MPYS tyrosine phosphorylation and SHP-1, SHIP recruitment [28]. Furthermore, overexpressing MPYS inhibited MHC class II induced Ca⁺ flux [28]. Thus, MPYS negatively regulates MHC class II signaling.

Li X. et al., recently found that the P_{8xxP}₁₁ of MPYS/STING can bind the Src tyrosine kinases [45]. Dong G. et al., further demonstrated that MPYS/STING inhibited JAK1-STAT1 signaling in B cells by the recruitment of SHP-1 and SHP-2 [46]. The authors proposed that the inhibitory function of MPYS/STING in B cells may prevent the development of B cell-dominant autoimmune disease [46].

2.4. Compartmentalization of the MHC class II signaling

Different from BCR, MHC class II is associated with a large group of four-transmembrane proteins called tetraspanins, which include CD9, CD20, CD37, CD38, CD53, CD63, CD81 and CD82 [47–51]. Tetraspanins are small hydrophobic proteins with four transmembrane domains, a small and a large extracellular loop and two short cytoplasmic tails [52,53]. Tetraspanins laterally organize membrane proteins to form tetraspanin-enriched microdomains [52,54]. A recent study using super-resolution microscopy found that tetraspanins form individual nanoclusters smaller than 120 nm and were distributed on the plasma membrane at densities of 1–5 domains per µm [53].

MHC class II was also reported in the “lipid rafts” microdomains [55]. Both lipid rafts microdomains and tetraspanin-enriched microdomains are resistant to non-ionic detergents, such as Triton X-100 [47,48]. Furthermore, depleting cholesterol with methyl β-cyclodextrin (MCD) disrupt both lipid rafts microdomains and tetraspanin-enriched microdomains [56,57]. Thus tetraspanin-enriched microdomains and lipid raft microdomains are likely inter-related [58]. It is possible that tetraspanin-enriched microdomains are one of many forms of lipid rafts.

MHC class II molecules loaded with specific antigenic peptides appear to be enriched in the tetraspanin-enriched microdomains [56]. CD19, SCIMP, and MPYS, which modulate MHC class II signaling are associated with tetraspanins [59]. CD19 forms a complex with tetraspanin CD81 [59]. SCIMP binds to tetraspanin CD37, CD53 and CD81 [42]. MPYS is a

four-transmembrane protein itself and binds to CD37 in B cells [28]. Thus, MHC class II signaling occurs in tetraspanin-enriched microdomains.

The compartmentalization of the MHC class II signaling likely reflects the need for MHC class II to recognize physically constrained membrane molecule, i.e., TCR, which exist as clusters on CD4⁺ T cell surface [60]. This is evident in BCR signaling, where BCR can recognize both soluble and membrane-bound antigens [61]. While CD19/CD81 tetraspanin complex is required for BCR recognition of membrane-bound antigens, they are dispensable for soluble antigens induced BCR activation [61].

In summary, CD79a/b mediates MHC class II-induced tyrosine phosphorylation and calcium mobilization in primed B cells. These signals are modulated by both positive co-receptors such as CD45, CD19 and negative co-receptors CD22 and MPYS. Last, MHC class II signaling is confined in the tetraspanin-enriched microdomains (Fig. 1).

2.5. Anti-MHC class II mAbs kill malignant B cells

Bridges S.H. et al., first found, in 1987, that anti-MHC class II mAbs killed B cell lymphoma in mice [62]. They found that ~50% of mice could be cured of lymphoma by multiple doses of anti-MHC class II mAb treatments [62]. They further suggested that anti-MHC class II inhibited tumor growth via a complement-independent mechanism [62]. Subsequent studies by many other labs found that anti-human HLA-DR mAbs could induce cell death in various malignant human B cells including the Burkitt lymphoma cells Raji and BJAB, B-lymphoblastoid cells ARH-77, LG-2, Hodgkin lymphoma cells HDML-2, L-428, L1236 cells, non-Hodgkin B cell lymphoma GRANTA-519 and primary B cell chronic lymphocytic leukemia samples [17–20]. Several studies reported anti-tumor activity of anti-HLA-DR mAbs [18,22,25,27]. Shi J. D. et al. found that the humanized mAb Hu1D10 (Apolizumab) rapidly and effectively depleted circulating B cells in rhesus monkeys for up to 10 days following the last dose [22]. Nagy Z.A. et al. found that another humanized anti-HLA-DR mAb 1D09C3 efficiently depleted B cells in cynomolgus monkeys [18]. 1D09C3 significantly prolonged the median survival times in SCID or NOD/SCID mice xenografted with human CLL line JVM-2 or MCL line GRANTA-519 [18,25].

Unlike other mAb-based therapies such as CD20 for lymphoid malignancies, anti-MHC class II therapy did not depend on complement-mediated lysis and/or antibody-dependent cell-mediated cytotoxicity [49]. Consequently, the anti-MHC class II mAb therapy depends less on the intact of the immune responses of patients and may also have fewer side-effects. Based on these promising characteristics, clinical trials were subsequently initiated [21,22,27].

2.6. Clinical trials of humanized anti-HLA-DR mAbs

Three Phase II clinical trials were conducted with Apolizumab (Hu1D10) on patients with progressive or recurrent Hodgkin's lymphoma ([ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT00055783): NCT00055783), patients with relapsed or refractory non-Hodgkin's lymphoma ([ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT00014664) Identifier: NCT00014664) and patients with chronic lymphocytic leukemia or small lymphocytic lymphoma ([ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT00089154) Identifier: NCT00089154). The overall clinical benefit was limited [21]. Some patients exhibited treatment-related dose-limiting toxicity (aseptic

meningitis, hemolytic uremia). Apolizumab was subsequently discontinued by the manufacturer [21].

1D09C3 clinical trials were conducted on patients with relapsed/refractory B cell type leukemia/lymphoma [27]. The treatment was well tolerated with mostly mild side effects [27]. However, 1D09C3 demonstrated limited activity clinically [27]. Furthermore, 1D09C3 was engineered with the Fc region of the IgG4 isotype [25]. It was later found that IgG4-type antibodies underwent Fab exchange with endogenous immunoglobulins in vivo [63]. In fact, 1D09C3 did undergo Fab arm exchange with other IgG4 molecules in a distinct redox environment in vitro [64]. Due to these concerns, the manufacturer halted further clinical development on 1D09C3.

IMMU-114, a new humanized IgG4 anti HLA-DR mAb, has recently undergone clinical trial ([ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT01728207) Identifier: NCT01728207) on patients with Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL). The initial results were promising including one NHL patient with a complete response [65]. Unlike Hu1D10 or 1D09c3, IMMU-114 was administered subcutaneously. The clinical trial was expected to be completed by the end of 2017.

2.7. The mechanisms of anti-MHC class II mAbs induced cell death

Anti-MHC class II mAbs induced cell death is mediated by MHC-II signaling [18] (Fig. 2). However, knocking down CD79b expression did not affect MHC class II induced cell death [16]. Moreover, DCs, which express MHC class II but not CD79a/b, were also killed by anti-MHC class II mAbs [66]. Thus, MHC class II-associated CD79a/b signaling is dispensable for cell death. MHC class II-mediated cell death did not require Src family kinase or caspase activation although mitochondrial cell death pathway was activated by anti-MHC class II mAbs [16,20,25,32]. Nevertheless, the exact molecular mechanism for anti-MHC class II mAbs induced cell death is controversial and likely depends on the mAbs and type of cells being targeted [67].

Protein kinase C activation was reportedly required for MHC-II-mediated death in Raji human B-cell lymphoma, mature DCs, and activated THP-1 monocytes but not in primary human plasmacytoid DCs [32,66,68]. Reactive oxygen species production and JNK kinase activation have been implicated in MHC class II-mediated death in lymphomas line JVM-2 and GRANTA-519 [25]. In 2009, Ivanov a. et al., reported that the anti-HLA-DR mAb L-243 induced cell death in Raji and primary chronic lymphocytic leukemia cells via the induction of homotypic adhesion and lysosome-mediated cell death pathway [69]. They observed that L-243 induced actin-dependent homotypic adhesion was sensitive to MCD depletion of membrane cholesterol [69]. They further found that homotypic adhesion led to lysosome swelling, which dispersed their contents into the cytoplasm [69]. Concanamycin A or bafilomycin A1, which inhibits vacuolar ATPases and prevents the acidification of organelles, reduced the cell death induced by L-243[69].

In 2008, we identified a new MHC class II-associated four-trans-membrane protein named MPYS [28]. We found that overexpressing MPYS inhibited B lymphoma cell growth and knocking down MPYS impaired anti-MHC class II mAbs induced cell death in the K46

mouse B lymphoma cells [28]. We further found that anti-MHC class II mAbs induced ERK activation in K46 cells and inhibited ERK activation by PD98059 reduced MHC class II induced cell death [28]. Last, we found that MPYS was required for anti-MHC class II mAbs induced ERK activation on the K46 cells [28].

In 2010, Stein R. et al. found that the humanized anti-HLA-DR mAb IMMU-114 induced cell death in leukemia, lymphoma, multiple myeloma cell lines and chronic lymphocytic leukemia patient specimens [23]. Furthermore, IMMU-114 induced disease-free survival in SCID mice xenografted with three non-Hodgkin lymphoma models [23]. Mechanistically, they found that the IMMU-114 cytotoxicity required the activation of ERK and JNK [23]. Blocking ERK activation by U0126 or knocking down ERK reduced IMMU-114 induced death in chronic lymphocytic leukemia patient samples [23].

2.8. The antiproliferative function of MPYS/STING

MPYS/STING is a four-transmembrane endoplasmic reticulum resident protein that plays a central role in DNA induced type I IFN production and proinflammatory responses [70]. STING exists as a homodimer [28] and undergoes a conformational change when binding to its physiological ligand 2'5'-cyclic GMP-AMP generated by cyclic GMP-AMP synthase (cGAS) upon sensing DNA [71]. Activated STING homodimer then traffics through Golgi to the perinuclear region where it activates TANK-Binding Kinase 1 (TBK1) leading to type I IFN production [71].

We first showed that overexpressing MPYS inhibited mouse B lymphoma cell growth [28]. Recently, the growth inhibition/anti-proliferative ability of MPYS/STING was observed in T cells [72]. Cerboni S. et al. found that the gain-of-function human STING mutant V155M inhibits T cell growth [72]. Surprisingly, they found that this antiproliferative function of MPYS/STING was independent of TBK1 and type I IFN [72]. They generated a STING mutant that can't bind TBK1 (deletion of aa 354–379) and found that it was still able to inhibit T cell growth. Neutralizing type I IFN did not abolish the anti-proliferative function of V155M of STING in T cells [72]. They identified that aa 343–354 of human STING is required for the growth inhibitory function of V155M of STING [72]. The same region is also required for NF- κ B activation [72]. The authors proposed that STING-mediated NF- κ B activation, not TBK1 activation, is responsible for the antiproliferative effect [72]. The activation of NF- κ B in T cells is associated with cell proliferation and differentiation [73]. How STING-mediated NF- κ B activation inhibits T cell growth remains to be determined. Interestingly, the antiproliferative function of the V155M was lost in the common human STING variant HAQ [72]. HAQ contains three non-synonymous SNPs, R71H-G230A-R293Q. HAQ is the second most common human *STING* allele [74]. It will be interesting to see if the HAQ individuals are prone to the development of B or T cell tumors due to their decreased antiproliferative function.

2.9. The apoptotic function of MPYS/STING

MPYS mediates anti-MHC class II mAbs induced cell death in mouse B lymphoma cells [28]. Recent studies found that directly activating MPYS/STING by its ligands can kill primary and malignant mouse B and T cells [75,76]. Interestingly, activation of STING in

mouse embryonic fibroblasts, bone marrow-derived macrophage and bone marrow-derived dendritic cells did not lead to cell death [75,76]. Notably, blocking type I IFN or type I IFN treatment did not alter STING-induced B or T cell death suggesting that the apoptotic function of STING/MPYS is independent of its ability to induce type I IFN [75,76]. The exact mechanism by which MPYS/STING induces cell death in B or T cells is unclear. However, it is worth noting that STING signaling in B and T cells is unique in the sense that the activation of STING does not lead to STING degradation [75,76].

2.10. STING expression in human B cells

In 2014, Liu Y. et al. reported no STING expression in human PBMC B cells [77]. This contradicted our discovery of MPYS/STING expression in mouse B cells [28]. Recently, we detected STING expression in dozens of Epstein–Barr virus (EBV) transformed human B cell lines derived from 1000Genome Project [74]. Dong G. et al., also confirmed STING expression in human B cells and showed that B cells from SLE patients had lower STING expression than the healthy controls [46]. Gram A. et al., reported STING expression in EBV positive human B cells and proposed a correlation between STING expression in human B cells and the status of EBV infection [78]. Considering that EBV is found in a vast majority of adults, most of human B cell samples should be STING positive.

Nevertheless, Liu Y. et al. did find that SAVI (STING-associated vasculopathy with onset in infancy) patients, which had the gain-of-function STING mutations, had elevated p-STAT1 in B cells [77]. Cerboni S. et al. found that PBMC from several SAVI patients had low percentages of CD27⁺/CD19⁺ memory B cells [72]. It remains to be determined if these B cells abnormalities in SAVI patients are B cell intrinsic.

3. Conclusion and future direction

In summary, MHC class II signaling in B cells, mediated predominantly by its associated CD79a/b, contribute to the thymus-dependent, early antigen-specific IgM Ab responses during cognate B-T cell interaction (Fig. 1). Also, MHC class II signaling activated by anti-MHC class II mAbs can kill malignant B cells via multiple mechanisms including MPYS/STING mediated antiproliferative/apoptotic signal (Fig. 2).

The life or death signaling of MHC class II probably takes place under different circumstances. As speculated above, the MHC class II/CD79a/b complex may represent the small population of cell surface MHC class II bound to the antigen-specific relevant peptide. Thus, the activation of MHC class II/CD79a/b occurs during the cognate B-T cells interaction. On the other hand, cross-linking MHC class II/HLA-DR with mAbs may engage a heterogeneous population of MHC class II complex on B cell surface including MHC class II bound to self-peptides and MHC class II with no peptide.

A major unanswered question is the physiological role of HLA-DR signaling in human B cells. Does HLA-DR signaling, like in the murine B cells, contribute to the optimal antigen-specific IgM production? Is HLA-DR signaling a unique feature of antigen-experienced human memory B cells? If so, does HLA-DR signaling in memory B cells influence the

vaccine responses? Mechanistically, does human HLA-DR employ CD79a/b for signaling? In this case, does the association depend on the connecting peptide region of HLA-DR?

Improving the efficacy of anti-HLA-DR mAbs for human cancers is another area worth further investigating. While promising in animal experiments, the efficacy of humanized anti-HLA-DR mAbs in human clinical trials was rather disappointing. We showed that MPYS/STING mediated MHC class II mAb-induced cell death in murine B lymphoma cells. It remains to be determined if the therapeutic effect of HLA-DR mAbs also require MPYS/STING especially for the IMMU-114, whose efficacy also depends on ERK activation. Notably, DMXAA [5,6-dimethylXAA (xanthone-4-acetic acid), Vadimezan, ASA404] a vascular-disrupting activity, which showed promising effects in Phase II clinical trials in non-small-cell lung cancer [79,80], failed in Phase III clinical trials [81,82]. Later, it was found that DMXAA activates murine MPYS/STING, but not human MPYS/STING [83]. Moreover, human *STING* gene is highly heterogeneous. Half of Americans have one copy of non-WT *STING* allele (the R232 of *STING*) [74,84]. If the anti-tumor activity of human HLA-DR mAbs depends on human *STING*, proper population stratification is needed in future human trials. In summary, understanding the molecular mechanism of the anti-tumor activity of HLA-DR mAbs is needed to advance their application in humans.

Acknowledgments

This work was supported by NIH grants AI110606 and AI125999 (to L.J.).

Abbreviations

Alum	aluminum hydroxide
APCs	antigen-presenting cells
ARD	antigen-recognition-domain
BCR	B cell receptor
CDNs	cyclic dinucleotides
cGAS	cyclic GMP-AMP synthase
DCs	dendritic cells
HAQ	R71 <u>H</u> -G230 <u>A</u> -R293Q
IFN	interferon
ITAM	immunoreceptor tyrosine-based activation motif
ITIM	immunoreceptor tyrosine-based inhibition motif
mAb	monoclonal antibody
MCD	methyl β -cyclodextrin
MPYS	N-Terminal <u>M</u> ethionine- <u>P</u> roline-Tyrosine- <u>S</u> erine tetraspanner

PI-3K	phosphoinositide 3-kinase
PLCγ2	phospholipase- C γ 2
SAVI	STING-associated vasculopathy with onset in infancy
SCIMP	SLP65/SLP76, Csk-interacting membrane protein
SHIP	SH2-domain-containing inositol phosphatase
STING	stimulator of interferon genes
Syk	spleen tyrosine kinase
TBK1	TANK-Binding Kinase 1
TCR	T cell receptor

References

- Giles JR, Kashgarian M, Koni PA, Shlomchik MJ. B cell-specific MHC class II deletion reveals multiple nonredundant roles for B cell antigen presentation in murine lupus. *J Immunol.* 1952015; : 2571–2579. [PubMed: 26268653]
- Molnarfi N, Schulze-Topphoff U, Weber MS, Patarroyo JC, Prod'homme T, Varrin-Doyer M, Shetty A, Linington C, Slavin AJ, Hidalgo J, Jenne DE, Wekerle H, Sobel RA, Bernard CC, Shlomchik MJ, Zamvil SS. MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. *J Exp Med.* 2102013; :2921–2937. [PubMed: 24323356]
- Shimoda M, Li T, Pihkala JP, Koni PA. Role of MHC class II on memory B cells in post-germinal center B cell homeostasis and memory response. *J Immunol.* 1762006; :2122–2133. [PubMed: 16455968]
- van Essen D, Kikutani H, Gray D. CD40 ligand-transduced co-stimulation of T cells in the development of helper function. *Nature.* 3781995; :620–623. [PubMed: 8524396]
- Chirmule N, Tazelaar J, Wilson JM. Th2-dependent B cell responses in the absence of CD40-CD40 ligand interactions. *J Immunol.* 1642000; :248–255. [PubMed: 10605018]
- Kawabe T, Naka T, Yoshida K, Tanaka T, Fujiwara H, Suematsu S, Yoshida N, Kishimoto T, Kikutani H. The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. *Immunity.* 11994; :167–178. [PubMed: 7534202]
- Castigli E, Alt FW, Davidson L, Bottaro A, Mizoguchi E, Bhan AK, Geha RS. CD40-deficient mice generated by recombination-activating gene-2-deficient blastocyst complementation. *Proc Natl Acad Sci USA.* 911994; :12135–12139. [PubMed: 7527552]
- Jordan MB, Mills DM, Kappler J, Marrack P, Cambier JC. Promotion of B cell immune responses via an alum-induced myeloid cell population. *Science.* 3042004; :1808–1810. [PubMed: 15205534]
- Lang P, Stolpa JC, Freiberg BA, Crawford F, Kappler J, Kupfer A, Cambier JC. TCR-induced transmembrane signaling by peptide/MHC class II via associated Ig-alpha/beta dimers. *Science.* 2912001; :1537–1540. [PubMed: 11222857]
- Mooney NA, Grillot-Courvalin C, Hivroz C, Ju LY, Charron D. Early biochemical events after MHC class II-mediated signaling on human B lymphocytes. *J Immunol.* 1451990; :2070–2076. [PubMed: 2398273]
- Cambier JC, Morrison DC, Chien MM, Lehmann KR. Modeling of T cell contact-dependent B cell activation. IL-4 and antigen receptor ligation primes quiescent B cells to mobilize calcium in response to Ia cross-linking. *J Immunol.* 1461991; :2075–2082. [PubMed: 1848577]
- Morio T, Geha RS, Chatila TA. Engagement of MHC class II molecules by staphylococcal superantigens activates src-type protein tyrosine kinases. *Eur J Immunol.* 241994; :651–658. [PubMed: 7510238]

13. Al-Daccak R, Mooney N, Charron D. MHC class II signaling in antigen-presenting cells. *Curr Opin Immunol.* 162004; :108–113. [PubMed: 14734118]
14. Cambier JC, Newell MK, Justement LB, McGuire JC, Leach KL, Chen ZZ. Ia binding ligands and cAMP stimulate nuclear translocation of PKC in B lymphocytes. *Nature.* 3271987; :629–632. [PubMed: 3037375]
15. Ma JK, Platt MY, Eastham-Anderson J, Shin JS, Mellman I. MHC class II distribution in dendritic cells and B cells is determined by ubiquitin chain length. *Proc Nat Acad Sci USA.* 1092012; :8820–8827. [PubMed: 22566640]
16. Jin L, Stolpa JC, Young RM, Pugh-Bernard AE, Refaeli Y, Cambier JC. MHC class II structural requirements for the association with Igalpha/beta, and signaling of calcium mobilization and cell death. *Immunol Lett.* 1162008; :184–194. [PubMed: 18194817]
17. Nagy ZA, Mooney NA. A novel, alternative pathway of apoptosis triggered through class II major histocompatibility complex molecules. *J Mol Med (Berl).* 812003; :757–765. [PubMed: 14551703]
18. Nagy ZA, Hubner B, Lohning C, Rauchenberger R, Reiffert S, Thomassen-Wolf E, Zahn S, Leyer S, Schier EM, Zahradnik A, Brunner C, Lobenstein K, Rattel B, Stanglmaier M, Hallek M, Wing M, Anderson S, Dunn M, Kretzschmar T, Tesar M. Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells. *Nat Med.* 82002; :801–807. [PubMed: 12101408]
19. Truman JP, Choqueux C, Tschopp J, Vedrenne J, Le Deist F, Charron D, Mooney N. HLA class II-mediated death is induced via Fas/Fas ligand interactions in human splenic B lymphocytes. *Blood.* 891997; :1996–2007. [PubMed: 9058721]
20. Drenou B, Blancheteau V, Burgess DH, Fauchet R, Charron DJ, Mooney NA. A caspase-independent pathway of MHC class II antigen-mediated apoptosis of human B lymphocytes. *J Immunol.* 1631999; :4115–4124. [PubMed: 10510346]
21. Lin TS, Stock W, Xu H, Phelps MA, Lucas MS, Guster SK, Briggs BR, Cheney C, Porcu P, Flinn IW, Grever MR, Dalton JT, Byrd JC. A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia. *Leuk Lymphoma.* 502009; :1958–1963. [PubMed: 19860603]
22. Shi JD, Bullock C, Hall WC, Wescott V, Wang H, Levitt DJ, Klingbeil CK. In vivo pharmacodynamic effects of Hu1D10 (remitogen), a humanized antibody reactive against a polymorphic determinant of HLA-DR expressed on B cells. *Leuk Lymphoma.* 432002; :1303–1312. [PubMed: 12153000]
23. Stein R, Gupta P, Chen X, Cardillo TM, Furman RR, Chen S, Chang CH, Goldenberg DM. Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways. *Blood.* 1152010; :5180–5190. [PubMed: 20101022]
24. Zola H, Beare A. 1D09C3, an mAb specific for MHC-II. *Curr Opin Mol Ther.* 102008; :68–74. [PubMed: 18228184]
25. Carlo-Stella C, Di Nicola M, Turco MC, Cleris L, Lavazza C, Longoni P, Milanesi M, Magni M, Ammirante M, Leone A, Nagy Z, Gioffre WR, Formelli F, Gianni AM. The anti-human leukocyte antigen-DR monoclonal antibody 1D09C3 activates the mitochondrial cell death pathway and exerts a potent antitumor activity in lymphoma-bearing nonobese diabetic/severe combined immunodeficient mice. *Cancer Res.* 662006; :1799–1808. [PubMed: 16452241]
26. Brown KS, Levitt DJ, Shannon M, Link BK. Phase II trial of Remitogen (humanized 1D10) monoclonal antibody targeting class II in patients with relapsed low-grade or follicular lymphoma. *Clin Lymphoma.* 22001; :188–190. [PubMed: 11779298]
27. Schweighofer CD, Tuchscherer A, Sperka S, Meyer T, Rattel B, Stein S, Ismail S, Elter T, Staib P, Reiser M, Hallek M. Clinical safety and pharmacological profile of the HLA-DR antibody 1D09C3 in patients with B cell chronic lymphocytic leukemia and lymphoma: results from a phase I study. *Cancer Immunol Immunother.* 612012; :2367–2373. [PubMed: 23090290]
28. Jin L, Waterman PM, Jonscher KR, Short CM, Reisdorph NA, Cambier JC. MPYS, a novel membrane tetraspanner, is associated with major histocompatibility complex class II and mediates transduction of apoptotic signals. *Mol Cell Biol.* 282008; :5014–5026. [PubMed: 18559423]

29. Wang HB, Weller PF. Pivotal advance: eosinophils mediate early alum adjuvant-elicited B cell priming and IgM production. *J Leukoc Biol.* 832008; :817–821. [PubMed: 18192490]
30. McKee AS, MacLeod M, White J, Crawford F, Kappler JW, Marrack P. Gr1+IL-4-producing innate cells are induced in response to Th2 stimuli and suppress Th1-dependent antibody responses. *Int Immunol.* 202008; :659–669. [PubMed: 18343889]
31. Bouillon M, El Fakhry Y, Girouard J, Khalil H, Thibodeau J, Mourad W. Lipid raft-dependent and -independent signaling through HLA-DR molecules. *J Biol Chem.* 2782003; :7099–7107. [PubMed: 12499388]
32. Guo W, Castaigne JG, Mooney N, Charron D, Al-Daccak R. Signaling through HLA-DR induces PKC beta-dependent B cell death outside rafts. *Eur J Immunol.* 332003; :928–938. [PubMed: 12672059]
33. Morbach H, Eichhorn EM, Liese JG, Girschick HJ. Reference values for B cell subpopulations from infancy to adulthood. *Clin Exp Immunol.* 1622010; :271–279. [PubMed: 20854328]
34. Dal Porto JM, Gauld SB, Merrell KT, Mills D, Pugh-Bernard AE, Cambier J. B cell antigen receptor signaling 101. *Mol Immunol.* 412004; :599–613. [PubMed: 15219998]
35. Cyster JG. B cell follicles and antigen encounters of the third kind. *Nat Immunol.* 112010; :989–996. [PubMed: 20959804]
36. Harwood NE, Batista FD. Visualizing the molecular and cellular events underlying the initiation of B-cell activation. *Curr Top Microbiol Immunol.* 3342009; :153–177. [PubMed: 19521685]
37. Harwood NE, Batista FD. Early events in B cell activation. *Annu Rev Immunol.* 282010; :185–210. [PubMed: 20192804]
38. Treanor B, Depoil D, Gonzalez-Granja A, Barral P, Weber M, Dushek O, Bruckbauer A, Batista FD. The membrane skeleton controls diffusion dynamics and signaling through the B cell receptor. *Immunity.* 322010; :187–199. [PubMed: 20171124]
39. Benschop RJ, Cambier JC. B cell development: signal transduction by antigen receptors and their surrogates. *Curr Opin Immunol.* 111999; :143–151. [PubMed: 10322153]
40. Bobbitt KR, Justement LB. Regulation of MHC class II signal transduction by the B cell coreceptors CD19 and CD22. *J Immunol.* 1652000; :5588–5596. [PubMed: 11067914]
41. Greer SF, Lin J, Clarke CH, Justement LB. Major histocompatibility class II-mediated signal transduction is regulated by the protein-tyrosine phosphatase CD45. *J Biol Chem.* 2731998; :11970–11979. [PubMed: 9565626]
42. Draber P, Vonkova I, Stepanek O, Hrdinka M, Kucova M, Skopцова T, Otahal P, Angelisova P, Horejsi V, Yeung M, Weiss A, Brdicka T. SCIMP, a transmembrane adaptor protein involved in major histocompatibility complex class II signaling. *Mol Cell Biol.* 312011; :4550–4562. [PubMed: 21930792]
43. Luo L, Bokil NJ, Wall AA, Kapetanovic R, Lansdaal NM, Marceline F, Burgess BJ, Tong SJ, Guo Z, Alexandrov K, Ross IL, Hibbs ML, Stow JL, Sweet MJ. SCIMP is a transmembrane non-TIR TLR adaptor that promotes proinflammatory cytokine production from macrophages. *Nat Commun.* 82017; :14133. [PubMed: 28098138]
44. Daron M, Jaeger S, Du Pasquier L, Vivier E. Immunoreceptor tyrosine-based inhibition motifs: a quest in the past and future. *Immunol Rev.* 2242008; :11–43. [PubMed: 18759918]
45. Li X, Yang M, Yu Z, Tang S, Wang L, Cao X, Chen T. The tyrosine kinase Src promotes phosphorylation of the kinase TBK1 to facilitate type I interferon production after viral infection. *Sci Signal.* 102017;
46. Dong G, You M, Ding L, Fan H, Liu F, Ren D, Hou Y. STING negatively regulates double-stranded DNA-activated JAK1-STAT1 signaling via SHP-1/2 in B cells. *Mol Cells.* 382015; :441–451. [PubMed: 25947293]
47. Zilber MT, Setterblad N, Vasselon T, Doliger C, Charron D, Mooney N, Gelin C. MHC class II/CD38/CD9: a lipid-raft-dependent signaling complex in human monocytes. *Blood.* 1062005; :3074–3081. [PubMed: 15941914]
48. Leveille C, R AL-D, Mourad W. CD20 is physically and functionally coupled to MHC class II and CD40 on human B cell lines. *Eur J Immunol.* 291999; :65–74. [PubMed: 9933087]

49. Szollosi J, Horejsi V, Bene L, Angelisova P, Damjanovich S. Supramolecular complexes of MHC class I, MHC class II, CD20, and tetraspan molecules (CD53, CD81, and CD82) at the surface of a B cell line JY. *J Immunol.* 1571996; :2939–2946. [PubMed: 8816400]
50. Angelisova P, Hilgert I, Horejsi V. Association of four antigens of the tetraspans family (CD37, CD53, TAPA-1, and R2/C33) with MHC class II glycoproteins. *Immunogenetics.* 391994; :249–256. [PubMed: 8119731]
51. Hammond C, Denzin LK, Pan M, Griffith JM, Geuze HJ, Cresswell P. The tetraspan protein CD82 is a resident of MHC class II compartments where it associates with HLA-DR, -DM, and -DO molecules. *J Immunol.* 1611998; :3282–3291. [PubMed: 9759843]
52. Charrin S, Jouannet S, Boucheix C, Rubinstein E. Tetraspanins at a glance. *J Cell Sci.* 1272014; :3641–3648. [PubMed: 25128561]
53. Zuidschewoude M, Gottfert F, Dunlock VM, Figdor CG, van den Bogaart G, van Sriel AB. The tetraspanin web revisited by super-resolution microscopy. *Sci Rep.* 52015; :12201. [PubMed: 26183063]
54. Hoorn T, Paul P, Janssen L, Janssen H, Neefjes J. Dynamics within tetraspanin pairs affect MHC class II expression. *J Cell Sci.* 1252012; :328–339. [PubMed: 22302999]
55. Anderson HA, Roche PA. MHC class II association with lipid rafts on the antigen presenting cell surface. *BBA.* 20151853; :775–780.
56. Bosch B, Heipertz EL, Drake JR, Roche PA. Major histocompatibility complex (MHC) class II-peptide complexes arrive at the plasma membrane in cholesterol-rich microclusters. *J Biol Chem.* 2882013; :13236–13242. [PubMed: 23532855]
57. Khandelwal S, Roche PA. Distinct MHC class II molecules are associated on the dendritic cell surface in cholesterol-dependent membrane microdomains. *J Biol Chem.* 2852010; :35303–35310. [PubMed: 20833718]
58. Zimmerman B, Kelly B, McMillan BJ, Seegar TCM, Dror RO, Kruse AC, Blacklow SC. Crystal structure of a full-length human tetraspanin reveals a cholesterol-binding pocket. *Cell.* 1672016; :1041–1051 e1011. [PubMed: 27881302]
59. Zimmerman B, Kelly B, McMillan BJ, Seegar TCM, Dror RO, Kruse AC, Blacklow SC. The CD19/CD81 complex physically interacts with CD38 but is not required to induce proliferation in mouse B lymphocytes. *Immunology.* 1372012; :48–55. [PubMed: 22564057]
60. Lillemeier BF, Mortelmaier MA, Forstner MB, Huppa JB, Groves JT, Davis MM. TCR and Lat are expressed on separate protein islands on T cell membranes and concatenate during activation. *Nat Immunol.* 112010; :90–96. [PubMed: 20010844]
61. Mattila PK, Feest C, Depoil D, Treanor B, Montaner B, Otipoby KL, Carter R, Justement LB, Bruckbauer A, Batista FD. The actin and tetraspanin networks organize receptor nanoclusters to regulate B cell receptor-mediated signaling. *Immunity.* 382013; :461–474. [PubMed: 23499492]
62. Bridges SH, Kruisbeek AM, Longo DL. Selective in vivo antitumor effects of monoclonal anti-I-A antibody on B cell lymphoma. *J Immunol.* 1391987; :4242–4249. [PubMed: 3500981]
63. Labrijn AF, Buijsse AO, van den Bremer ET, Verwilligen AY, Bleeker WK, Thorpe SJ, Killestein J, Polman CH, Aalberse RC, Schuurman J, van de Winkel JG, Parren PW. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. *Nat Biotechnol.* 272009; :767–771. [PubMed: 19620983]
64. Hansen K, Ruttekolk IR, Glauner H, Becker F, Brock R, Hannus S. The in vitro biological activity of the HLA-DR-binding clinical IgG4 antibody 1D09C3 is a consequence of the disruption of cell aggregates and can be abrogated by Fab arm exchange. *Mol Immunol.* 462009; :3269–3277. [PubMed: 19699529]
65. Stephens DM, Starodub AN, Byrd JC, Horne H, Wegener WA, Goldenberg DM, Christian BA. Subcutaneous injections of IMMU-114 (Anti-HLA-DR IgG4 monoclonal antibody): initial results of a phase I first-in-man study in hematologic malignancies. *Blood.* 1262015; :2740.
66. Bertho N, Blancheteau VM, Setterblad N, Laupeze B, Lord JM, Drenou B, Amiot L, Charron DJ, Fauchet R, Mooney N. MHC class II-mediated apoptosis of mature dendritic cells proceeds by activation of the protein kinase C-delta isoenzyme. *Int Immunol.* 142002; :935–942. [PubMed: 12147630]

67. Haylett RS, Koch N, Rink L. MHC class II molecules activate NFAT and the ERK group of MAPK through distinct signaling pathways in B cells. *Eur J Immunol.* 392009; :1947–1955. [PubMed: 19544309]
68. Drenou B, Amiot L, Setterblad N, Taque S, Guilloux V, Charron D, Fauchet R, Mooney N. MHC class II signaling function is regulated during maturation of plasmacytoid dendritic cells. *J Leukoc Biol.* 772005; :560–567. [PubMed: 15647325]
69. Ivanov A, Beers SA, Walshe CA, Honeychurch J, Alduaij W, Cox KL, Potter KN, Murray S, Chan CH, Klymenko T, Erenpreisa J, Glennie MJ, Illidge TM, Cragg MS. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. *J Clin Invest.* 1192009; :2143–2159. [PubMed: 19620786]
70. Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. *Nature.* 4552008; :674–678. [PubMed: 18724357]
71. Kato K, Omura H, Ishitani R, Nureki O. Cyclic GMP-AMP as an endogenous second messenger in innate immune signaling by cytosolic DNA. *Annu Rev Biochem.* 862017; :541–566. [PubMed: 28399655]
72. Cerboni S, Jeremiah N, Gentili M, Gehrmann U, Conrad C, Stolzenberg MC, Picard C, Neven B, Fischer A, Amigorena S, Rieux-Laucat F, Manel N. Intrinsic antiproliferative activity of the innate sensor STING in T lymphocytes. *J Exp Med.* 2142017; :1769–1785. [PubMed: 28484079]
73. Oh H, Ghosh S. NF-kappaB: roles and regulation in different CD4(+) T-cell subsets. *Immunol Rev.* 2522013; :41–51. [PubMed: 23405894]
74. Patel S, Blaauboer SM, Tucker HR, Mansouri S, Ruiz-Moreno JS, Hamann L, Schumann RR, Opitz B, Jin L. The common R71H–G230A–R293Q human TMEM173 is a null allele. *J Immunol.* 1982017; :776–787. [PubMed: 27927967]
75. Gulen MF, Koch U, Haag SM, Schuler F, Apetoh L, Villunger A, Radtke F, Ablasser A. Signalling strength determines proapoptotic functions of STING. *Nat Commun.* 82017; :427. [PubMed: 28874664]
76. Tang CH, Zundell JA, Ranatunga S, Lin C, Nefedova Y, Del Valle JR, Hu CC. Agonist-mediated activation of STING induces apoptosis in malignant B cells. *Cancer Res.* 762016; :2137–2152. [PubMed: 26951929]
77. Liu Y, Jesus AA, Marrero B, Yang D, Ramsey SE, Sanchez GAM, Tenbrock K, Wittkowski H, Jones OY, Kuehn HS, Lee CR, DiMattia MA, Cowen EW, Gonzalez B, Palmer I, DiGiovanna JJ, Biancotto A, Kim H, Tsai WL, Trier AM, Huang Y, Stone DL, Hill S, Kim HJ, Hilaire CS, Gurprasad S, Plass N, Chapelle D, Horkayne-Szakaly I, Foell D, Barysenka A, Candotti F, Holland SM, Hughes JD, Mehmet H, Issekutz AC, Raffeld M, McElwee J, Fontana JR, Minniti CP, Moir S, Kastner DL, Gadina M, Steven AC, Wingfield PT, Brooks SR, Rosenzweig SD, Fleisher TA, Deng Z, Boehm M, Paller AS, Goldbach-Mansky R. Activated STING in a vascular and pulmonary syndrome. *N Engl J Med.* 3712014; :507–518. [PubMed: 25029335]
78. Gram AM, Sun C, Landman SL, Oosenbrug T, Koppejan HJ, Kwakkenbos MJ, Hoeben RC, Paludan SR, Rensing ME. Human B cells fail to secrete type I interferons upon cytoplasmic DNA exposure. *Mol Immunol.* 912017; :225–237. [PubMed: 28968560]
79. Pili R, Rosenthal MA, Mainwaring PN, Van Hazel G, Srinivas S, Dreicer R, Goel S, Leach J, Wong S, Clingan P. Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC. *Clin Cancer Res.* 162010; :2906–2914. [PubMed: 20460477]
80. McKeage MJ, Reck M, Jameson MB, Rosenthal MA, Gibbs D, Mainwaring PN, Freitag L, Sullivan R, Von Pawel J. Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. *Lung Cancer.* 652009; :192–197. [PubMed: 19409645]
81. Lara PN, Douillard JY, Nakagawa K, von Pawel J, McKeage MJ, Albert I, Losonczy G, Reck M, Heo DS, Fan X, Fandi A, Scagliotti G, et al. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. *J Clin Oncol.* 292011; :2965–2971. [PubMed: 21709202]
82. Lorusso PM, Boerner SA, Hunsberger S. Clinical development of vascular disrupting agents: what lessons can we learn from ASA404? *J Clin Oncol.* 292011; :2952–2955. [PubMed: 21709201]

83. Conlon J, Burdette DL, Sharma S, Bhat N, Thompson M, Jiang Z, Rathinam VA, Monks B, Jin T, Xiao TS, Vogel SN, Vance RE, Fitzgerald KA. Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid. *J Immunol.* 1902013; :5216–5225. [PubMed: 23585680]
84. Jin L, Xu LG, Yang IV, Davidson EJ, Schwartz DA, Wurfel MM, Cambier JC. Identification and characterization of a loss-of-function human MPYS variant. *Genes Immun.* 122011; :263–269. [PubMed: 21248775]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Fig. 1.

Cognate B cell–T cell interaction activates CD79a/b mediated MHC class II signaling in B cells. In primed B cells, MHC class II is associated with CD79a/b. The activation of CD79a/b leads to phosphorylation of their ITAM that leads to downstream tyrosine phosphorylation and calcium mobilization. CD19 and CD45 can enhance MHC class II signaling while the ITIM-containing molecules CD22 and MPY/STING inhibit MHC class II Igα/β signaling. CD19, MPYS/STING and MHC class II are in the tetraspanins-enriched microdomains. The MHC Class II signaling during the cognate B–T cells interaction contributes to the early antigen-specific IgM production.

Fig. 2.

Anti-MHC class II mAbs induce cell death in malignant B cells. Humanized anti-MHC class II mAbs kill malignant B cells via multiple mechanisms.